Physician profile
Jesse R Gettinger
NPI 1760061642
$1,024.83
in general payments reported to CMS, 2019-2025
17 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $323 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.88 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239.68 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $121.86 | 2024-2025 | |
| Abbott Laboratories | $91.62 | 2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.14 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $68.78 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $52.39 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.64 | 2025 | Jardiance |
| Novo Nordisk INC | $48.52 | 2024-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $47.52 | 2024-2025 | |
| Hydrocision, INC. | $40.74 | 2024 | Tenjet |
| Vanda Pharmaceuticals INC. | $37.10 | 2025 | Fanapt |
| Aimmune Therapeutics, INC. | $30.33 | 2025 | Vowst |
| Exact Sciences Corporation | $29.69 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $22.15 | 2025 | |
| Amgen INC. | $20.25 | 2024 | Prolia, Evenity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.25 | 2024 | Gardasil 9, Gardasil, Vaxelis |
| Seqirus USA INC | $16.17 | 2024 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Gettinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.